Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial

BackgroundIn the randomized, controlled, phase III KEYNOTE-061 trial, second-line pembrolizumab did not significantly prolong overall survival (OS) versus paclitaxel in patients with PD-L1-positive (combined positive score ≥1) advanced gastric/gastroesophageal junction (G/GEJ) cancer but did elicit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal for ImmunoTherapy of Cancer Jg. 11; H. 6; S. e006920
Hauptverfasser: Shitara, Kohei, Di Bartolomeo, Maria, Mandala, Mario, Ryu, Min-Hee, Caglevic, Christian, Olesinski, Tomasz, Chung, Hyun Cheol, Muro, Kei, Goekkurt, Eray, McDermott, Raymond S, Mansoor, Wasat, Wainberg, Zev A, Shih, Chie-Schin, Kobie, Julie, Nebozhyn, Michael, Cristescu, Razvan, Cao, Z Alexander, Loboda, Andrey, Özgüroğlu, Mustafa
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England BMJ Publishing Group Ltd 01.06.2023
BMJ
BMJ Publishing Group LTD
BMJ Publishing Group
Schriftenreihe:Original research
Schlagworte:
ISSN:2051-1426, 2051-1426
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!